Competitive Outlook on Non-Antibody Based Cancer Vaccines

Table of Contents

1 Executive Summary

2 Cancer Highlights

3 Methodology

• 4 Table of Contents
• 4.1 List of Boxes
• 4.2 List of Figures
• 4.3 List of Tables

5 Vaccine Strategies: Challenges & Opportunities

6 Competitive Landscape in Cancer Vaccines

• 6.1 Countries & Players: Who are In the Lead?
  • 6.1.1 Top 10 Players Constitute Up to One Third of R&D: Big Pharma Not Included!
  • 6.1.2 Approved Cancer Vaccine Drugs: Performance
• 6.2 Deals & Alliances in Cancer Vaccines
  • 6.2.1 Recent Mergers & Acquisitions in Cancer Vaccines
  • 6.2.2 Deals in Prostate Cancer
  • 6.2.3 Deals in Breast Cancer
  • 6.2.4 Deals in Leukemia & Lymphoma
  • 6.2.5 Drug Delivery Deals in Cancer Vaccines
  • 6.2.6 Adjuvant Deals

7 Tumor Antigens

• 7.1 Tumor Antigens: General Comments
• 7.2 Antigen Discovery
  • 7.2.1 Classical Immunology Approach
  • 7.2.2 The Reverse Immunology Approach
  • 7.2.3 Company Platforms
    • 7.2.3.1 Epitope Identification System - EIS®
    • 7.2.3.2 EPIQUEST system
    • 7.2.3.3 MolecularBreeding™ & MaxyScan™
    • 7.2.3.4 ProtEx™ technology
    • 7.2.3.5 Rapid Identification of Alternative Splicing (RIAS) System
    • 7.2.3.6 SMARTOMICS™
• 7.3 Specific Antigen Processing Technologies Increasing Antigen Presentation

8 Immunomodulators & Adjuvants in Cancer Vaccines

• 8.1 Overview
• 8.2 Cytokines
  • 8.2.1 Vaccines in Combination with Interleukin-2
  • 8.2.2 Tumor Necrosis Factor
  • 8.2.3 Interferons
• 8.3 Adjuvants
• 8.4 Other Immunomodulating Strategies
  • 8.4.1 An Immune Response Modifying Protein
  • 8.4.2 Immunostimulatory DNA
  • 8.4.3 Ex Vivo Stimulated Immune Cells
  • 8.4.4 Fusion Protein Gain Potent Immune Response
  • 8.4.5 Macrophage and Natural Killer Cells Activation
  • 8.4.6 Selective Suppression of the Immune System to An Antigen
  • 8.4.7 TAP Technology

9 Cancer Vaccine Delivery

• 9.1 Viral Delivery
  • 9.1.1 Introduction
  • 9.1.2 Viral Constructs Put into Use
    • 9.1.2.1 Replicon-based RNA and DNA vaccines
      • 9.1.2.1.1 The Alphavaccine Platform System - ArV™
      • 9.1.2.1.2 MVA-BN
    • 9.1.2.2 Retroviruses
      • 9.1.2.2.1 The SDSV-platform
    • 9.1.2.3 Lentivirus
      • 9.1.2.3.1 LentiPak™
      • 9.1.2.3.2 LentiVector™⁄ pEGASUS™
    • 9.1.2.4 Adenoviruses
      • 9.1.2.4.1 Failed Adenovirus Delivery Platforms
      • 9.1.2.4.2 GVAX
      • 9.1.2.4.3 TNFerade™
      • 9.1.2.4.4 INGN-225
    • 9.1.2.5 Adeno-associated viruses
      • 9.1.2.5.1 Failed AAV Delivery Platforms
      • 9.1.2.5.2 Genzyme Acquires AAV vector Technology
      • 9.1.2.5.3 MediGene's AAV Platform
    • 9.1.2.6 Herpes Simplex Viruses
      • 9.1.2.6.1 DISC-HSV
      • 9.1.2.6.2 ImmunoVEX
    • 9.1.2.7 Poxviruses
      • 9.1.2.7.1 Hi-8™ PrimeBoost™ platform
      • 9.1.2.7.2 PROSTVAC-VF
      • 9.1.2.7.3 Transgene's MVA Platform
      • 9.1.2.7.4 TroVax
    • 9.1.2.8 Other Poxvirus Systems
    • 9.1.2.9 Baculovirus
    • 9.1.2.9.1 Chimeric virus -like particles (CVLPs)
• 9.2 Bacterias
• 9.3 Cell Therapy: Dendritic-cell Based & Cancer-Cell Based Therapies
  • 9.3.1 Introduction
  • 9.3.2 Cell Therapy Strategies
    • 9.3.2.1 Processed Tumor Cells
    • 9.3.2.2 Lysed Tumor Cell Line
    • 9.3.2.3 The Dendritic Cell Strategy that Didn't Work Out
    • 9.3.2.4 HSPs
    • 9.3.2.5 Provenge™
    • 9.3.2.6 Dendritophages
    • 9.3.2.7 Cell-targeting Antibodies
    • 9.3.2.8 Increase Dendritic Cell Number
    • 9.3.2.9 DCVax®
    • 9.3.2.10 ACTIVATE™
• 9.4 Synthetic Delivery Systems & Strategies
  • 9.4.1 Introduction
  • 9.4.2 Biotransport™
  • 9.4.3 Biotype®vector
  • 9.4.4 DNAVax Gene Delivery System
  • 9.4.5 FusitAb™
  • 9.4.6 GeneDrug™
  • 9.4.7 Molecular Conjugates
  • 9.4.8 Naked DNA Delivery
  • 9.4.9 PVLP Technology
  • 9.4.10 Sphingosomal Drug Delivery Technology
  • 9.4.11 STEALTH
  • 9.4.12 Failed Liposomal Systems

10 Non-Antibody Based Vaccines in Development: By Major Indications

• 10.1 General Oncology Overview
• 10.2 Progress Analysis - Melanoma
• 10.3 Progress Analysis - Breast Cancer
• 10.4 Progress Analysis - Prostate Cancer
• 10.5 Progress Analysis - Lung Cancer
• 10.6 Progress Analysis - Colorectal Cancer
• 10.7 Progress Analysis - Cervical Cancer

11 Disclaimer

• 11.1 Liability
• 11.2 Completeness

12 Drug Index

13 Company Index